Drug Approval | June 16, 2023
Briefs: Natco Pharma and Panacea Biotec
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
The company will submit its comprehensive response on these observations to the US FDA
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
_256_384.jpeg)
Launched Pathology Laboratory in Vijayawada offering a wide range of best-in-class diagnostic services with over 2500+ tests
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
Coverage of CGHS cities has expanded from 25 cities in 2014 to 80 in 2023
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
The EU certification will support supplies of drug products registered in Europe, from this manufacturing site
New facility will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics for patients worldwide.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
